Presence of Reactive Microglia in Monkey Substantia Nigra Years after 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Administration

Annals of Neurology

Volumn 54, Issue 5, 2003, Pages 599-604

  McGeer, Patrick L ^a   Schwab, Claudia ^a   Parent, Andre ^b   Doudet, Doris ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; HLA DR ANTIGEN; ISOFLURANE; KETAMINE; LEVODOPA; MELANIN; PENTOBARBITAL;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; DOPAMINERGIC NERVE CELL; DRUG EXPOSURE; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MICROGLIA; MONKEY; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

AGED; AGED, 80 AND OVER; ANIMALS; EXTRACELLULAR MATRIX; FEMALE; HLA-DR ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; MACACA MULATTA; MALE; MELANINS; MICROGLIA; MPTP POISONING; NEURONS; PARKINSON DISEASE; SUBSTANTIA NIGRA; TIME FACTORS;

EID: 0242384667     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10728     Document Type: Article

References (33)

1. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980.
2. Chiba K, Trevor AJ, Castagnoli N Jr. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 1984;120:574-578.
3. Langston JW, Irwin I, Langston EB, Forno LS. 1-Methyl-4-phenylpyridium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci Lett 1984;48:87-92.
4. Ramsay RR, Salach JI, Singer TP. Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+. Biochem Biophys Res Comm 1986;13:743-748.
5. Vingerhoets FJG, Snow BJ, Tetrud JW, et al. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann Neurol 1994;36:765-770.
6. Langston JW, Forno LS, Tetrud J, et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999;46:598-605.
7. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988;38:1285-1291.
8. McGeer PL, Itagaki S, Akiyama H, McGeer EG. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 1988;24:574-576.
9. Fernandez-Ruiz J, Doudet DJ, Aigner TG. Cognitive improvement of levodopa in parkinsonian MPTP-treated monkeys. Psychopharmacology 1999;147:104-107.
10. Doudet DJ, Chan GLY, Holden JE, et al. 6-[18F]fluoro-L-dopa PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys. Synapse 1998;29:225-232.
11. Charara A, Parent A. Brainstem dopaminergic, cholinergic and serotoninergic afferents to the pallidum in the squirrel monkey. Brain Res 1994;640:155-170.
12. Schwab C, Steele JC, McGeer PL. Neurofibrillary tangles of Guam Parkinson-dementia are associated with reactive microglia and complement proteins. Brain Res 1996;707:196-205.
13. McGeer PL, McGeer EG, Suzuki J Aging and extrapyramidal function. Arch Neurol 1977;34:33-35.
14. Naoi M, Maruyama W. Cell death of dopamine neurons in aging and Parkinson's disease. Mech Ageing Dev 1999;111:175-188.
15. Chu Y, Kompaliti K, Cochran EJ, et al. Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J Comp Neurol 2002;450:203-214.
16. Aimi Y, McGeer PL. Lack of toxicity of human neuromelanin to rat brain dopaminergic neurons. Parkinsonism Relat Disord 1996;2:69-74.
17. Calne DB, Lees AJ. Late progression of post-encephalitic Parkinson's syndrome. Can J Neurol Sci 1988;15:135-138.
18. Mawdsley C, Ferguson FR. Neurological disease in boxers. Lancet 1963;2:795-801.
19. Marey-Samper I, Gelman M, Levi-Strauss M. The high sensitivity to rotenone of striatal dopamine uptake suggests the existence of a constitutive metabolic deficiency in dopaminergic neurons from the substantia nigra. Eur J Neurosci 1993;5:1029-1034.
20. Betarbet R, Sherer TB, MacKenzie G, et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000;3:1301-1306.
21. Hattori N, Tanaka M, Ozawa T, Mizuno Y. Immunohistochemical studies on complexes I, II, III and IV of mitochondria in Parkinson's disease. Ann Neurol 1991;30:563-571.
22. Schapira AH, Cooper JM, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990;54:823-827.
23. DiDonato S, Zeviani M, Giovannini P, et al. Respiratory chain and mitochondrial DNA in muscle and brain in Parkinson's disease patients. Neurology 1993;43:2262-2268.
24. Chen H, Zhabd SM, Hernan MA, et al. Nonsteroidal antiinflammatory drugs and the risk of Parkinson's disease. Movement Dis 2002;17(suppl 5):S143-S144.
25. Veld BA, Ruitenberg A, Hofman A, et al. Non-steroidal antiinflammatory drug use and risk of Alzheimer's disease. N Engl J Med 2001;345:1515-1521.
26. Zandi PP, Anthony JC, Hayden KM, et al. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 2002;59:880-886.
27. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 1995;21:195-218.
28. Akiyama H, Barger S, Barnum S, et al. Neuroinflammation Working Group. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421.
29. McGeer PL, Yasojima K, McGeer EG. Association of interleukin-1β polymorphisms with idiopathic Parkinson's disease. Neurosci Lett 2002;326:67-69.
30. Schulte T, Schols L, Muller T, et al. Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson's disease. Neurosci Lett 2000;326:70-72.
31. Nicoll JAR, Mrak RE, Graham D, et al. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol 2000;47:365-368.
32. Kowall NW, Hantraye P, Brouillet E, et al. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport 2000;11:211-213.
33. Vila M, Vukosavic S, Jackson-Lewis V, et al. α-Synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the Parkinsonian toxin MPTP. J Neurochem 2000;74:721-729.